BioCentury | Aug 3, 2018

Lin’s new chapters

Taiwanese biotech Lin Bioscience Inc. and its wholly owned San Diego subsidiary Lin Bioscience Co. Ltd. are planning sequential listings in Taiwan and the U.S. to fund clinical programs targeting different markets. Lin has two...
BC Week In Review | Oct 27, 2017
Clinical News

Cancer Research UK begins Phase I of Lilly's CDC7 inihibitor in solid tumors

Cancer Research UK (London, U.K.) began a Phase I trial of LY3143921 to treat advanced solid tumors, including bowel, lung, ovarian, urothelial, pancreatic, breast, head and neck, and esophageal tumors in about 68 patients. The...
BC Innovations | Apr 21, 2017
Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
BC Week In Review | Mar 24, 2017
Company News

Columbia University, Memorial Sloan Kettering, Lin BioScience deal

The university and Memorial Sloan granted Lin BioScience exclusive, worldwide rights to LBS-007 and related IP. Lin said the small molecule that inhibits cell division cycle 7-related protein kinase (CDC7) has shown preclinical effectiveness against...
BioCentury | Dec 14, 2015
Product Development

Following CoMMpass

Amidst a flood of promising data for hot targets, indications and technologies at this year's American Society of Hematology meeting, one collection of presentations stands out not only for the wide-reaching implications of their data,...
BC Week In Review | Sep 1, 2014
Company News

Nerviano, Ignyta deal

Nerviano granted Ignyta exclusive, worldwide rights to develop and commercialize preclinical cancer programs RXDX-103 and RXDX-104 . Nerviano will receive $3.5 million up front and is eligible for up to $68 million in milestones for RXDX-103...
BC Innovations | Oct 11, 2012

Leukemia team building

The Leukemia & Lymphoma Society has announced its first research partnership with a large biopharma company-a four-year, multimillion-dollar deal with Celgene Corp. to solicit and fund proposals from academics and smaller biotechs. The not-for-profit organization...
BC Week In Review | Feb 16, 2009
Clinical News

NMS-354: Phase I start

This quarter, Nerviano will begin a U.S. Phase I trial in 20-30 patients. Nerviano Medical Sciences s.r.l. , Nerviano, Italy   Product: NMS-354   Business: Cancer   Molecular target: NA   Description: CDC7 protein kinase inhibitor...
BioCentury | Dec 15, 2008

BMS cancer pipeline

BMS cancer pipeline Compound [partner] Target Lead indication Status Erbitux cetuximab [Merck KGaA (Xetra:MRK)/Eli Lilly (NYSE:LLY)] Epidermal growth factor (EGF) receptor 1 (HER1) (ErbB1) Colorectal cancer; squamous cell carcinoma of the head and neck (SCCHN)...
BC Week In Review | Dec 8, 2008
Company News

Exelixis, Bristol-Myers deal

Bristol-Myers exercised its option to develop and commercialize XL413 , triggering a $20 million milestone payment to Exelixis. In October, Exelixis submitted a data report to the pharma for the selective inhibitor of cell division cycle...
Items per page:
1 - 10 of 14